Asymmetric synthesis of 2-substituted chroman-4-ones using lipase-catalyzed kinetic resolutions
摘要:
2-Methylchroman-4-one and 2-phenylchroman-4-one were synthesized in optically active form. Their chiral intermediates were obtained via lipase-catalyzed enantioselective reactions. (C) 2003 Elsevier Science Ltd. All rights reserved.
Minimizing Aryloxy Elimination in Rh
<sup>I</sup>
‐Catalyzed Asymmetric Hydrogenation of β‐Aryloxyacrylic Acids using a Mixed‐Ligand Strategy
作者:Yang Li、Zheng Wang、Kuiling Ding
DOI:10.1002/chem.201503229
日期:2015.11.9
The first example of efficientasymmetrichydrogenation of challenging β‐aryloxyacrylic acids was realized using a RhI‐complex based on the heterocombination of a readilyavailable chiral monodentate secondary phosphine oxide (SPO) and an achiral monodentate phosphine ligand as the catalyst. Excellent enantioselectivities (92–>99 % ee) were achieved for a wide variety of chiral β‐aryloxypropionic acids
The present invention provides for compounds of formula (I)
wherein X, Y, and R
1
have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN
申请人:AbbVie S.à.r.l.
公开号:US20170305891A1
公开(公告)日:2017-10-26
The present invention provides for compounds of formula (I)
wherein R
1
, m, Z, G
1
, R
2
, and R
3
have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
Chiral chromanols and their derivatives have been synthesized via a RuPHOX–Ru catalyzedasymmetrichydrogenation of chromones in high yields, >20 : 1 drs and with up to 99.9% ee. Control experiments show that the reaction undergoes two sequential asymmetrichydrogenation steps of the CC and CO double bonds. The reaction could be performed on a gram-scale with a relatively low catalyst loading (up to
通过RuPHOX-Ru催化色酮的不对称氢化,以高产率,> 20:1 drs和最高99.9%ee合成了手性苯甲酚及其衍生物。对照实验表明,该反应经历了C C和C O双键的两个连续的不对称氢化步骤。该反应可以以克级进行,具有相对较低的催化剂负载量(最高1000 S / C),并且所得产物可以转化为几种生物活性化合物。
Diastereoselective conjugate addition to 3-(p-tolylsulphinyl)chromone: a route to chiral 2-substituted chroman-4-ones
作者:Suthiweth T. Saengchantara、Timothy W. Wallace
DOI:10.1039/c39860001592
日期:——
Conjugate addition of lithium dimethylcuprate to 3-(p-tolylsulphinyl)chromone (1) proceeds with at least 90% diastereoselectivity, and the products from (S)-(1) can be converted into chiral 2-methylchroman-4-one (–)-(16).